Sunday, June 14, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 277 of 1,261

  1. US 11274305

    Compositions and methods for in vivo excision of HIV-1 proviral DNA

    United States Government as represented by the Department of Veterans Affairs · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted

  2. US 11274303

    Olmalinc as a diagnostic and therapeutic target for NAFLD, NASH, metabolic syndrome, and hepatic fibrosis

    The United States Government represented by the Department of Veterans Affairs · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted

  3. US 11274294

    TAL effector-mediated DNA modification

    Regents of the University of Minnesota · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted

  4. US 11274163

    Ultra-stable protein ionic liquids

    United States of America as represented by the Secretary of the Air Force · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted

  5. US 11274282

    Vesicular stomatitis vectors encoding Crimean-Congo hemorrhagic fever antigen

    The Board of Regents of the University of Texas System · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted

  6. US 11274130

    HV1 modulators and uses

    The Regents of the University of California · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted

  7. US 11274101

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted

  8. US 11274123

    1,2,4-oxadiazole compounds as inhibitors of CD47 signalling

    Aurigene Discovery Technologies Limited · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted

  9. US 11273214

    Recombinant chimeric bovine/human parainfluenza virus 3 expressing RSV G and its use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted

  10. US 11274077

    4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase

    The United States of America Department of Health · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted

  11. US 11273431

    Biologically applicable water-soluble heterogeneous catalysts for para-hydrogen induced polarization

    The Regents of the University of California · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted

  12. US 11273191

    Administering compositions for improved immune system functioning

    Script Essentials, LLC · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted

  13. US 11273181

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted

  14. US 11273180

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted

  15. US 11273131

    Pharmaceutical compositions with enhanced permeation

    Aquestive Therapeutics, Inc. · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted

  16. US 11273167

    Compositions and methods for modulating ABHD2 activity

    The Regents of the University of California · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted

  17. US 11273132

    Topical dapsone and dapsone/adapalene compositions and methods for use thereof

    ALMIRALL, LLC · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted

  18. US 11273127

    Compositions, methods and uses for thermally stable multi-targeted antigens

    The Regents of the University of Colorado, a Body Corporate · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted

  19. US 11273130

    Methods of delivering a neuroprotective polypeptide to the central nervous system

    The United States, as represented by the Secretary Department of Health and Human Services · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted

  20. US 2022072166

    METHOD OF TREATMENT OF NEUROENDOCRINE TUMORS

    ADVANCED ACCELERATOR APPLICATIONS S A [FR] · Granted Mar 10, 2022 · Expires Mar 5, 2042

    granted

  21. EP 3964220

    PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR BEHANDLUNG VON OSTEOPOROSE

    BIOCODEX [FR] · Granted Mar 9, 2022 · Expires Mar 4, 2042

    granted

  22. US 11267893

    Anti-IL36R antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 8, 2022 · Expires Mar 3, 2042

    granted

  23. US 11266622

    Method of treatment

    VANDA PHARMACEUTICALS INC. · Granted Mar 8, 2022 · Expires Mar 3, 2042

    granted

  24. US 11266726

    Compositions and methods for the treatment of HER2-expressing solid tumors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 8, 2022 · Expires Mar 3, 2042

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.